Why the study?
The potential mechanism of pyrvinium pamoate for inhibiting Mycobacterium tuberculosis-induced inflammation remained unexplored.
Does pyrvinium pamoate suppress NLRP3 inflammasome activation and pyroptosis in mycobacteria-infected human macrophages?
Population
Human THP-1-derived macrophages infected with M.tb, S. typhimurium, or treated with LPS
Comparison
Pyrvinium pamoate treatment vs control
Design
In vitro laboratory study
Authors
Loading...
Pyrvinium pamoate merits exploration as TB host-directed therapy; leaves open translation from animal models to human efficacy.
Does pyrvinium pamoate suppress NLRP3 inflammasome activation and pyroptosis in mycobacteria-infected human macrophages?
Pyrvinium pamoate suppresses mycobacteria-induced NLRP3 inflammasome activation and pyroptosis by targeting CK1α pathways, suggesting potential as a host-directed therapy for tuberculosis.
Guan et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: